Profile
| Metric | Value |
|---|---|
| Full Name | Jazz Pharmaceuticals plc |
| Ticker | NASDAQ: JAZZ |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Country | Ireland |
| IPO | |
| Indexes | Not included |
| Website | jazzpharma.com |
| Employees | 2,800 |
Key Metrics
| Metric | Date | Value |
|---|---|---|
| Price | $173.15 | |
| Price, 1D Change | +1.85% | |
| Market Cap | $11B | |
| - | ||
| PE Ratio | - | |
| Beta | 0.75 | |
| Revenue | $4B | |
| Revenue, 1Y Change | +6.12% | |
| EPS | $8.65 | |
| EPS, 1Y Change | +41.75% |
Chart
Add series to chart(max: 6)
Series
SUGGESTED SERIES
Events
| Metric | Date | Value |
|---|---|---|
| Next Earnings | ||
| Last Qtr. Earnings | ||
| Last Ann. Earnings | ||
| Last Ex-Dividend | N/A | N/A |
| Next Ex-Dividend | N/A | N/A |
| Last Split | N/A | N/A |
| Next Split | N/A | N/A |
| Last Ticker Change | N/A | N/A |
| Next Ticker Change | N/A | N/A |
🔒 Log In To Unlock Full Data
Estimates
| Metric | Date | Value |
|---|---|---|
| EPS | $8.65 | |
| EPS Estimate | $8.10 | |
| EPS Est. Change | -6.31% | |
| Revenue | $4.07B | |
| Revenue Estimate | $4.23B | |
| Revenue Est. Change | +3.96% | |
| Current Price | $173.15 | |
| Price Target | - | $210.00 |
| Price Tgt. Change | - | +21.28% |
🔒 Log In To Unlock Full Data
EPS
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| $18.44 | $6.10 | -66.91% | |
| $20.21 | $8.65 | -57.21% | |
| $8.10 | N/A | -6.31% | |
| $22.62 | N/A | +161.59% |
Revenue
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| $3.83B | $3.83B | +0.02% | |
| $4.04B | $4.07B | +0.70% | |
| $4.23B | N/A | +3.96% | |
| $4.50B | N/A | +10.60% |
🔒 Log In To Unlock Full Data
Performance
| Metric | Date | Value |
|---|---|---|
| Price, 1Y | +39.91% | |
| Price, 3Y | +8.69% | |
| Market Cap, 1Y | +40.22% | |
| Market Cap, 3Y | +4.48% | |
| Revenue, 1Y | +6.12% | |
| Revenue, 3Y | +31.50% | |
| EPS, 1Y | +41.75% | |
| EPS, 3Y | +256.61% |
🔒 Log In To Unlock Full Data
Technical Indicators
| Metric | Date | Value |
|---|---|---|
| Current Price | $173.15 | |
| SMA 200 | $128.00 | |
| SMA 200 vs Price | -26.08% | |
| SMA 50 | $158.75 | |
| SMA 50 vs Price | -8.31% | |
| Beta | 0.75 | |
| ATR | $4.02 | |
| 14-Day RSI | 62.90 | |
| 10-Day Volatility | 12.18% | |
| 1-Year Volatility | 39.47% |
Dividends
| Metric | Date | Value |
|---|---|---|
| N/A | - | |
| Upcoming | N/A | N/A |
| - | ||
| - | ||
| Dividends Paid | $0.00 | |
| Payout Ratio | 0.00% |
🔒 Log In To Unlock Full Data
Income & Profitability
| Metric | Date | Value |
|---|---|---|
| Revenue | $4.07B | |
| EPS | $8.65 | |
| Gross Profit | $3.00B | |
| Gross Margin | 73.63% | |
| Operating Profit | $726.63M | |
| Operating Margin | 17.86% | |
| Net Income | $560.12M | |
| Net Margin | 13.77% | |
| EBITDA | $1.39B |
🔒 Log In To Unlock Full Data
Financial Health
| Metric | Date | Value |
|---|---|---|
| Debt To Equity | 1.51 | |
| Current Ratio | 4.46 | |
| Quick Ratio | 3.99 | |
| - | ||
| F-Score | 4 | |
| Altman Z-Score | 1.82 |
Valuations
| Metric | Date | Value |
|---|---|---|
| PE Ratio | - | |
| PS Ratio | 2.53 | |
| PB Ratio | 2.66 | |
| EV/EBITDA | 11.58 | |
| Enterprise Value | N/A | - |
Balance Sheet
| Metric | Date | Value |
|---|---|---|
| Book Value | $4.09B | |
| Cash & Equivalents | $2.99B | |
| Total Assets | $12.01B | |
| Current Assets | $4.63B | |
| Total Liabilities | $7.92B | |
| Current Liabilities | $1.04B | |
| Total Debt | $6.17B | |
| Short Term Debt | $45.78M | |
| Accounts Payable | $77.87M |
Expenses
| Metric | Date | Value |
|---|---|---|
| Total Expenses | $3.51B | |
| Operating Expenses | $2.27B | |
| Cost Of Goods Sold | $1.07B | |
| SG&A | $0.00 | |
| D&A | $660.07M | |
| Interest Expense | $0.00 | |
| Income Tax | -$91.43M |
Cash Flow
| Metric | Date | Value |
|---|---|---|
| CFO | $1.40B | |
| CFI | -$508.20M | |
| CFF | $20.52M | |
| Capex | $38.07M | |
| Free Cash Flow | $1.36B |
Recent analyst updates
| Metric | Date | Value |
|---|---|---|
| Piper Sandler | → | |
| UBS | → | |
| Wells Fargo | → | |
| Baird | → | |
| B of A Securities | → | |
| RBC Capital | → | |
| Morgan Stanley | → | |
| RBC Capital | → | |
| JP Morgan | → | |
| Morgan Stanley | → |
Analyst sentiment
Institutional ownership
Screeners with JAZZ
Data Sources & References
- JAZZ Official Website www.jazzpharma.com
- Most Recent Quarterly Report (10-Q) www.sec.gov/Archives/edgar/data/1232524/000123252425000074/0001232524-25-000074-index.htm
- Most Recent Annual Report (10-K) www.sec.gov/Archives/edgar/data/1232524/000123252425000011/0001232524-25-000011-index.htm
- JAZZ Profile on Yahoo Finance finance.yahoo.com/quote/JAZZ
- JAZZ Profile on NASDAQ.com www.nasdaq.com/market-activity/stocks/jazz
FAQ
What is the ticker symbol for Jazz Pharmaceuticals plc?
The ticker symbol for Jazz Pharmaceuticals plc is NASDAQ:JAZZ
Does Jazz Pharmaceuticals plc pay dividends?
No, Jazz Pharmaceuticals plc does not pay dividends
What sector is Jazz Pharmaceuticals plc in?
Jazz Pharmaceuticals plc is in the Healthcare sector
What industry is Jazz Pharmaceuticals plc in?
Jazz Pharmaceuticals plc is in the Biotechnology industry
What country is Jazz Pharmaceuticals plc based in?
Jazz Pharmaceuticals plc is headquartered in Ireland
When did Jazz Pharmaceuticals plc go public?
Jazz Pharmaceuticals plc initial public offering (IPO) was on June 1, 2007
Is Jazz Pharmaceuticals plc in the S&P 500?
No, Jazz Pharmaceuticals plc is not included in the S&P 500 index
Is Jazz Pharmaceuticals plc in the NASDAQ 100?
No, Jazz Pharmaceuticals plc is not included in the NASDAQ 100 index
Is Jazz Pharmaceuticals plc in the Dow Jones?
No, Jazz Pharmaceuticals plc is not included in the Dow Jones index
When was Jazz Pharmaceuticals plc last earnings report?
Jazz Pharmaceuticals plc's most recent earnings report was on November 5, 2025
When does Jazz Pharmaceuticals plc report earnings?
The next expected earnings date for Jazz Pharmaceuticals plc is February 24, 2026